Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Recap by typeshit. Post by Avi Roy on X.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
8:32
Archibald follows up his earlier retatrutide video with a look at its uses. Retatrutide is still an investigational drug and is not FDA approved.
Gilead takes global rights to the Shanghai biotech's program, led by HCXT-2001, an oral peptide that could compete with injected IBD drugs.
A Facebook promo for a podcast episode on the ripple effects of GLP-1 consumers across businesses. Few details beyond the pitch.
Loading…